Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ...

Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. Learn more about DYN stock here.

RNA interference (RNAi) therapeutics are based on a natural process by which RNA sequences ... For people with Duchenne muscular dystrophy, these drugs have been a significant step towards their care.

This abnormal RNA accumulates and disturbs the proper production of proteins important for muscle ... for patients with disease-causing mutations in the DMD gene amenable to exon 51 skipping. Dyne ...

Researchers have now uncovered the 3D structure of the RNA enzyme SAMURI. Their study provides insights into the development of ribozymes and the evolution of catalytically active RNA. Researchers ...

该研究揭示了肠道沙门氏菌如何通过非编码小RNA在转录后水平协调N-乙酰神经氨酸代谢过程中不同氨基糖操纵子转录产物的机制。 唾液酸是一类以九碳糖神经氨酸为基本结构的衍生物。生命体中常见的唾液酸为N-乙酰神经氨酸，富集于哺乳动物上皮细胞表面。

Exon skipping, which ultimately leads to functional ... This was the first-ever proof of RNA editing in humans, according to the company. Data showed that 006 was successful in ...